中航证券发布研报称，国内外医疗公司持续布局AI产品与服务，包括医学影像、临床辅助决策、精准 医疗、健康管理、医疗信息化、药物研发以及医疗机器人等，通过降本增效、改善患者体验、降低患病 风险等方式全面赋能医药、医疗各个环节。AI正从"技术辅助"角色，升级为医疗产业"价值重塑"和"效 率革命"的核心驱动力，其商业价值正在从研发端向临床端、支付端和患者端全面渗透。 中航证券主要观点如下： 国内方面本月看点 AI制药领域，AI在早期药物研发中的价值正逐步得到临床验证。英矽智能通过AI平台发现新药临床试 验申请获得美国FDA批准，显示出"同类最佳"潜力；晶泰科技孵化企业莱芒生物展示了其极低剂量 CAR-T疗法的研究者发起临床(IIT)最新成果。AI辅诊领域，AI大模型正在向诊断、分诊、健康管理等 广泛医疗场景的渗透与落地，主要进展包括：宫颈细胞数字病理AI辅助诊断软件获批，体外诊断龙头 企业宣布加速AI医疗领域布局，华工科技（000988）发布"医疗智能体"等。基础模型方面，国内各类大 模型企业跑步入场，中国团队首登Nature子刊发布医疗大模型评判标准，显示出中国医疗大模型的国际 竞争力。生物医学科技前沿方面，AI影 ...

Core Insights - The report emphasizes the strong growth potential in the testing services industry, particularly driven by emerging sectors such as commercial aerospace and new technologies [4][6] - The testing services sector is closely linked to macroeconomic growth, with a projected global market size of approximately 2.3 trillion RMB by 2024, reflecting a CAGR of about 6% from 2021 to 2024 [4][24] - In China, the testing services market is expected to reach around 487.6 billion RMB by 2024, with a CAGR of approximately 10.5% from 2015 to 2024, indicating a robust growth trajectory [5][24] Industry Overview - The testing, inspection, and certification (TIC) industry serves various sectors including consumer goods, industrial products, and pharmaceuticals, covering all stages from R&D to production and distribution [16][24] - The industry is characterized by a large market space and stable growth, with demand closely tied to macroeconomic trends and government regulations [20][24] - Emerging technologies such as AI, electric vehicles, and commercial aerospace are expected to create new testing demands, raising the entry barriers for new players [6][20] Company Performance - The report analyzes 19 listed companies in the testing services sector, highlighting their revenue and profit performance, with notable companies including Huace Testing, Guangdian Measurement, and Su Testing [2][11] - In the first three quarters of 2025, the testing services sector in China reported a revenue of 30.4 billion RMB, a decline of 7% year-on-year, but a growth of 3% when excluding companies heavily involved in medical testing [5][57] - Leading companies such as Huace Testing, Guangdian Measurement, and Su Testing demonstrated superior performance, with revenue growth rates of 7%, 12%, and 9% respectively, significantly outpacing the industry average [5][62] Market Dynamics - The testing services market is experiencing a structural shift, with a trend towards consolidation as larger firms gain market share and smaller firms face challenges [44][50] - The report notes that the majority of testing institutions in China are small and micro-sized, which limits their ability to withstand economic pressures [50][51] - Government policies are increasingly supporting the marketization and consolidation of testing institutions, aiming to enhance the overall quality and efficiency of the industry [51][53] Financial Metrics - The report indicates that the average gross margin for the testing services sector has improved, reaching 26.2% in the first three quarters of 2025, reflecting a recovery in profitability [63] - The accounts receivable turnover days have increased from 90 days in 2019 to 176 days in 2025, indicating a slowdown in cash flow and potential credit risks within the industry [67][68] - The report highlights that the proportion of accounts receivable in relation to revenue has risen to 50%, suggesting increasing challenges in managing receivables [71]

Summary of Conference Call Notes Industry Focus - The focus is on the **AI healthcare sector**, particularly the integration of artificial intelligence in medical applications and services [1][2]. Core Insights and Arguments - The **Chinese government** emphasizes the need to promote large-scale commercial applications of AI, aiming to enhance the AI industry and expand high-value application scenarios [1]. - Recent advancements include **DeepSeek's version update** and the launch of **GLM-5**, indicating continuous breakthroughs in AI models [2]. - The **AI healthcare sector** is gaining traction due to supportive policies, technological advancements, and the gradual commercialization of pathology-assisted diagnostics [2]. - Clear application scenarios for AI in healthcare have been identified: - **B-end applications**: Involvement in medical imaging, surgical robots, in vitro diagnostics, and radiotherapy. - **C-end applications**: Empowering health management, chronic disease monitoring, personalized treatment suggestions, and academic research for doctors [2]. - Continuous policy support is evident through various documents that outline development directions and commercial pathways for AI in healthcare [2]. - The **first inclusion of "AI-assisted"** in the pricing project guidelines for pathology services marks a significant step towards commercialization [2]. - National-level AI application pilot platforms are being promoted in regions like **Beijing and Zhejiang**, enhancing industry conversion efficiency [2]. Additional Important Content - The **AI application market** is experiencing a surge in interest, driven by competition among major tech companies (ByteDance, Tencent, Alibaba, Baidu) in the general AI application field [3]. - Recent achievements, such as **ByteDance's Seedance 2.0**, demonstrate a shift from mere generation capabilities to commercial viability [3]. - The performance of companies like **Tempus** supports the feasibility of AI healthcare business models [3]. - Investment recommendations include companies such as **Dian Diagnostics, KingMed Diagnostics, and Meinian Health** [4]. - Risks highlighted include potential delays in policy implementation and slow commercialization of products or services [5].

Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

Group 1 - Guangzhou held a commendation conference recognizing 60 outstanding non-public economic individuals and 20 enterprises for their contributions to the construction of socialism with Chinese characteristics [1] - The Secretary of the Guangzhou Municipal Committee emphasized the importance of non-public economic individuals and private enterprises in participating in key projects such as the Guangdong-Hong Kong-Macao Greater Bay Area development and modern industrial system construction [1] - The government aims to optimize the business environment and support enterprises in Guangzhou by protecting private property rights and enhancing policy implementation [1] Group 2 - The Chairman and CEO of Kingmed Diagnostics expressed commitment to fostering young entrepreneurs and promoting national integration while driving innovation in biotechnology and information technology [2] - EHang's CEO highlighted the importance of aligning corporate development with urban growth, focusing on the low-altitude economy to establish Guangzhou as a hub for this industry [2] - Miniso, a retail brand originating from Guangzhou, plans to lead 100 Chinese original IPs overseas in the next decade, leveraging Guangzhou's manufacturing base and open business environment [2] Group 3 - Haida Group, the first agricultural leader in Guangzhou to exceed 100 billion yuan in revenue, aims to strengthen its core research advantages and contribute to making Guangzhou a global agricultural technology hub [3] - The group is focused on advancing marine breeding technologies and enhancing mechanisms to support rural development initiatives [3]

（文章来源：证券日报） 证券日报网讯 1月30日，金域医学在互动平台回答投资者提问时表示，公司预计2025年年度实现归属于 上市公司股东的净利润为-13，000万元到-19，000万元，与上年同期相比，将同比减亏19，124.11万元 到25，124.11万元。 ...

Group 1 - The Nipah virus outbreak in West Bengal, India has led to confirmed cases and significant market reactions, particularly in vaccine and diagnostic sectors, with several stocks experiencing price surges [1][2] - The Nipah virus, first identified in 1998, has a high fatality rate exceeding 40% and lacks effective treatments, which raises public health concerns and market volatility [2][3] - Despite initial market enthusiasm, the lack of confirmed cases in China and the limited geographical impact of the outbreak have resulted in a significant stock price correction for related companies [1][4] Group 2 - Companies like Capbio, Zhijiang Bio, and others have developed Nipah virus testing products, but the overall demand for testing has not increased significantly due to the outbreak, leading to continued financial pressure on these firms [4][10] - The medical testing industry, previously buoyed by COVID-19 testing, is now facing declining revenues as demand decreases, with many companies reporting substantial losses [9][10] - The vaccine sector is also under pressure, with companies like Zhifei and Watson facing intense competition and declining sales, leading to significant financial challenges [15][20] Group 3 - The overall performance of companies in the vaccine and diagnostic sectors is expected to remain under pressure due to economic cycles, increased competition, and regulatory changes affecting pricing and profitability [12][20] - The Nipah virus outbreak has not translated into increased orders for testing products from domestic companies, indicating a lack of substantial market opportunity arising from the situation [12][22] - Investors are advised to be cautious, as the Nipah virus may not provide the expected boost to the performance of the medical testing and vaccine industries, which are already struggling with profitability [22]

二、分配方案 1.发放年度：2025年前三季度 2.分派对象： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案经广州金域医学检验集团股份有限公司（以下简称"公司"）2026年1月21日的2026年 第一次临时股东会审议通过。 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本463,258,275股为基数，每股派发现金红利0.88元（含税），共 计派发现金红利407,667,282.00元。 三、相关日期 ■ 四、分配实施办法 1.实施办法 除公司自行发放对象外，其余股东的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上 海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易 的投资者可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中国结 算上海分公司保管，待办理指定交易后再进 ...

证券代码：603882 证券简称：金域医学 公告编号：2026-011 广州金域医学检验集团股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 每股分配比例 A股每股现金红利0.88元 2.自行发放对象 ● 相关日期 ■ ● 差异化分红送转： 否 一、通过分配方案的股东会届次和日期 本次利润分配方案经广州金域医学检验集团股份有限公司（以下简称"公司"）2026年1月21日的2026年 第一次临时股东会审议通过。 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本463,258,275股为基数，每股派发现金红利0.88元（含税），共 计派发现金红利407,667,282.00元。 三、相关日期 1.实施办法 除公司自行发放对象外，其余股东的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上 海证券 ...

证券日报网讯 1月28日，金域医学发布公告称，金域医学2025年前三季度利润分配方案：A股每股派发 现金红利0.88元（含税），股权登记日2026年2月4日，除权除息日及红利发放日均为2026年2月5日，总 计派息约4.08亿元。 （编辑 丛可心） ...